# Neutral control output

> Prompt: *"Read it and give your feedback on it."* (verbatim subagent output)

---

## Overall

The one-pager reads well and is honest in spots (it flags the economics as first-pass estimates), but as a basis for a "wider rollout" decision it has serious credibility and safety gaps. The headline metrics and the "ready for wider rollout" conclusion are not supported by the evidence described — and for a clinical triage tool that's the difference between a pitch and a liability.

## Blocking issues (must fix before any rollout claim)

1. **Single-site, single-scanner data invalidates the headline metrics.** All 50,000 training AND validation scans come from one hospital, one Siemens scanner, 2023-2024. The "held-out test set" is therefore from the same distribution — it shows the model memorized Riverside/Siemens, not that it generalizes. The 94% / 0.97 AUC almost certainly drops on any other site or scanner vendor. "State-of-the-art" is unsupportable without an external test set and a named benchmark/comparator.
2. **"94% accuracy" is the wrong metric and may be hiding the important number.** Abnormality screening is class-imbalanced. If ~15% of scans are abnormal, a model that calls everything "clear" scores 85% accuracy while missing every sick patient. For a triage tool the decision-relevant metrics are **sensitivity/recall and the false-negative rate**, plus specificity and PPV. Report those, with confidence intervals.
3. **The 0.5 threshold is asserted, not justified.** For triage you almost never want the default 0.5 — you tune the operating point to the clinically acceptable miss rate (high sensitivity). State how the threshold was chosen and what sensitivity/specificity it yields.
4. **The pilot can't support its conclusion.** n=30, same hospital, "agreed in the large majority of cases" and "felt faster" are subjective and unquantified. No measured time-to-read improvement, no inter-rater stats, no comparison, no missed-case count. Anecdote, not evidence — and it's the only real-world data.
5. **"Bottom line: ready for a wider rollout" is not earned.** The supported conclusion is "promising internal results; needs external validation + a prospective, powered pilot before rollout."

## Significant issues

6. **"Real time" contradicts "6 minutes per scan."** Pick one and define it.
7. **The $2M/year is built on an unvalidated assumption stacked on the unvalidated pilot.** Credit for flagging it as first-pass — but the "8 minutes saved" input has no source, and the pilot didn't measure time saved. Also note the 8-min vs 6-min inconsistency reads as a contradiction side-by-side.
8. **No safety/failure-mode discussion at all.** What happens to false negatives? How are clinicians told this is decision-support not diagnosis? Without this the tool can cause harm by lulling readers into trusting the order.

## Minor / wording
9. "utilizes" → "uses"; "trained end-to-end" adds nothing decision-relevant.
10. "state-of-the-art" — drop unless you cite the benchmark and comparators.
11. Define "abnormal" — scope materially changes how the metrics should be read.

## Bottom line
The strongest, most honest version reframes the conclusion from "ready for wider rollout" to "strong single-site results; next step is external validation and a prospective powered pilot reporting sensitivity/specificity and measured time-saved." Fixing the single-site gap (1), reporting sensitivity/false-negative rate (2), and softening the bottom line (5) matter most.

---

*Scoring note: found all 4 real flaws and ranked them — but ~11 findings, more verbose, no explicit "what's fine to skip", and it surfaces several legitimate-but-secondary items (safety discussion, "define abnormal") at a similar weight. Solid; less tightly actionable than the calibrated pass.*
